RU2014149348A - Предотвращение, разрушение и обработка биопленки лизином бактериофага - Google Patents
Предотвращение, разрушение и обработка биопленки лизином бактериофага Download PDFInfo
- Publication number
- RU2014149348A RU2014149348A RU2014149348A RU2014149348A RU2014149348A RU 2014149348 A RU2014149348 A RU 2014149348A RU 2014149348 A RU2014149348 A RU 2014149348A RU 2014149348 A RU2014149348 A RU 2014149348A RU 2014149348 A RU2014149348 A RU 2014149348A
- Authority
- RU
- Russia
- Prior art keywords
- biofilm
- seq
- polypeptide
- lysine
- composition
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract 15
- 239000004472 Lysine Substances 0.000 title claims abstract 15
- 230000006378 damage Effects 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 241001515965 unidentified phage Species 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 20
- 229920001184 polypeptide Polymers 0.000 claims abstract 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 18
- 239000000203 mixture Substances 0.000 claims abstract 13
- 241000192125 Firmicutes Species 0.000 claims abstract 8
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 8
- 230000003115 biocidal effect Effects 0.000 claims abstract 7
- 150000001413 amino acids Chemical group 0.000 claims abstract 6
- 229940088710 antibiotic agent Drugs 0.000 claims abstract 6
- 108010013198 Daptomycin Proteins 0.000 claims abstract 5
- 108010059993 Vancomycin Proteins 0.000 claims abstract 5
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims abstract 5
- 229960005484 daptomycin Drugs 0.000 claims abstract 5
- 229960003165 vancomycin Drugs 0.000 claims abstract 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims abstract 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims abstract 5
- 241000295644 Staphylococcaceae Species 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 4
- 230000009089 cytolysis Effects 0.000 claims abstract 4
- 239000007943 implant Substances 0.000 claims abstract 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims abstract 4
- 229960003907 linezolid Drugs 0.000 claims abstract 4
- 230000002934 lysing effect Effects 0.000 claims abstract 4
- 241000894006 Bacteria Species 0.000 claims abstract 3
- 230000001580 bacterial effect Effects 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/40—Viruses, e.g. bacteriophages
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ предотвращения, разрушения или обработки биопленки грамположительных бактерий, включающий контактирование биопленки с композицией, содержащей полипептид лизина, способный к лизису стафилококков, где биопленку эффективно предотвращают, диспергируют или обрабатывают.2. Способ по п. 1, где полипептид лизина представляет собой PlySs2.3. Способ по п. 2, где полипептид лизина содержит аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1) или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и является эффективным для лизиса грамположительных бактерий в биопленке.4. Способ по п. 1, где композиция дополнительно содержит один или несколько антибиотиков.5. Способ по п. 4, где антибиотик выбирают из даптомицина, ванкомицина и линезолида.6. Способ по п. 1, дополнительно включающий контактирование биопленки с одним или несколькими антибиотиками.7. Способ предотвращения или снижения образования биопленки грамположительных бактерий, включающий контактирование медицинского устройства, катетера или имплантата с композицией, содержащей полипептид лизина, способный к лизису стафилококков, где лизин представляет собой PLySs2.8. Способ по п. 7, где полипептид лизина содержит аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1), или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и является эффективным для предотвращения или снижения образования бактериальной биопленки или прикрепления и роста бактерий на медицинских устройствах, катетере или имплантате.9. Способ по п. 7, где композиция дополнительно содержит антибиотик.10. Способ по п. 9, где антибиотик выбирают из даптомицина, ванкомиц
Claims (15)
1. Способ предотвращения, разрушения или обработки биопленки грамположительных бактерий, включающий контактирование биопленки с композицией, содержащей полипептид лизина, способный к лизису стафилококков, где биопленку эффективно предотвращают, диспергируют или обрабатывают.
2. Способ по п. 1, где полипептид лизина представляет собой PlySs2.
3. Способ по п. 2, где полипептид лизина содержит аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1) или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и является эффективным для лизиса грамположительных бактерий в биопленке.
4. Способ по п. 1, где композиция дополнительно содержит один или несколько антибиотиков.
5. Способ по п. 4, где антибиотик выбирают из даптомицина, ванкомицина и линезолида.
6. Способ по п. 1, дополнительно включающий контактирование биопленки с одним или несколькими антибиотиками.
7. Способ предотвращения или снижения образования биопленки грамположительных бактерий, включающий контактирование медицинского устройства, катетера или имплантата с композицией, содержащей полипептид лизина, способный к лизису стафилококков, где лизин представляет собой PLySs2.
8. Способ по п. 7, где полипептид лизина содержит аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1), или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и является эффективным для предотвращения или снижения образования бактериальной биопленки или прикрепления и роста бактерий на медицинских устройствах, катетере или имплантате.
9. Способ по п. 7, где композиция дополнительно содержит антибиотик.
10. Способ по п. 9, где антибиотик выбирают из даптомицина, ванкомицина и линезолида или родственного соединения.
11. Композиция для применения при предотвращении, разрушении или обработке биопленки грамположительных бактерий, содержащая полипептид лизина, содержащий аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1), или ее варианты, имеющую по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и являющийся эффективным для лизиса грамположительных бактерий в биопленке.
12. Композиция по п. 11, дополнительно содержащая один или несколько антибиотиков.
13. Композиция по п. 12, где антибиотик выбирают из даптомицина, ванкомицина и линезолида или родственного соединения.
14. Композиция для предотвращения, разрушения или обработки стрептококковой или стафилококковой бактериальной биопленки, содержащая полипептид лизина, содержащий аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1), или ее варианты, имеющую по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и являющийся эффективным для лизиса стафилококковых или стрептококковых бактерий.
15. Композиция по п. 14, дополнительно содержащая один или несколько антибиотиков.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644799P | 2012-05-09 | 2012-05-09 | |
| US61/644,799 | 2012-05-09 | ||
| US201261736813P | 2012-12-13 | 2012-12-13 | |
| US61/736,813 | 2012-12-13 | ||
| PCT/US2013/040340 WO2013170022A1 (en) | 2012-05-09 | 2013-05-09 | Biofilm prevention, disruption and treatment with bacteriophage lysin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018102796A Division RU2735103C2 (ru) | 2012-05-09 | 2013-05-09 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014149348A true RU2014149348A (ru) | 2016-07-10 |
| RU2646102C2 RU2646102C2 (ru) | 2018-03-01 |
Family
ID=49551275
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018102796A RU2735103C2 (ru) | 2012-05-09 | 2013-05-09 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
| RU2014149348A RU2646102C2 (ru) | 2012-05-09 | 2013-05-09 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
| RU2020133461A RU2020133461A (ru) | 2012-05-09 | 2020-10-12 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018102796A RU2735103C2 (ru) | 2012-05-09 | 2013-05-09 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020133461A RU2020133461A (ru) | 2012-05-09 | 2020-10-12 | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9499594B2 (ru) |
| EP (2) | EP2846827B1 (ru) |
| JP (4) | JP6348901B2 (ru) |
| KR (4) | KR20210118980A (ru) |
| CN (2) | CN104780933B (ru) |
| AU (3) | AU2013259427B2 (ru) |
| BR (1) | BR112014027818B1 (ru) |
| CA (2) | CA3187222A1 (ru) |
| DK (1) | DK2846827T3 (ru) |
| ES (1) | ES2729123T3 (ru) |
| HK (2) | HK1208366A1 (ru) |
| IL (2) | IL235526B2 (ru) |
| IN (1) | IN2014MN02438A (ru) |
| MX (2) | MX369056B (ru) |
| RU (3) | RU2735103C2 (ru) |
| WO (1) | WO2013170022A1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2664708C1 (ru) * | 2017-06-08 | 2018-08-21 | Сергей Иванович Черныш | Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0811530B1 (pt) | 2007-05-14 | 2019-01-02 | Research Foundation Of State Univ Of New York | composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície |
| IL235527B2 (en) * | 2012-05-09 | 2023-10-01 | Contrafect Corp | Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria |
| GB2543453A (en) | 2014-06-26 | 2017-04-19 | Univ Rockefeller | Acinetobacter lysins |
| CN104805066B (zh) * | 2015-05-18 | 2018-04-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
| EP3120866A1 (en) * | 2015-07-24 | 2017-01-25 | Zymetech ehf. | Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms |
| WO2017134661A1 (en) | 2016-02-04 | 2017-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods for disrupting biofilms |
| JP2019510076A (ja) * | 2016-02-19 | 2019-04-11 | フォルシュングスツェントルム ボルシュテル ライプニッツツェントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 細菌感染症を治療するための手段と方法 |
| CN112118861A (zh) * | 2018-02-26 | 2020-12-22 | 康特拉费克特公司 | 修饰的PlySs2溶素及其用途 |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020198073A1 (en) * | 2019-03-22 | 2020-10-01 | Contrafect Corporation | Method of treating infective endocarditis |
| JP2022526624A (ja) * | 2019-04-11 | 2022-05-25 | コントラフェクト コーポレイション | 骨及び関節の感染を治療及び予防する方法 |
| KR102097128B1 (ko) * | 2019-06-19 | 2020-04-06 | 서울대학교산학협력단 | 황색포도상구균 제어에 효과적인 키메릭 엔도라이신 Lys109 |
| CN111019876B (zh) * | 2019-12-30 | 2023-04-28 | 延安大学 | 一种铜绿假单胞菌工程菌的构建方法及应用 |
| IL297953A (en) * | 2020-05-19 | 2023-01-01 | Contrafect Corp | Modified plyss2 lysines and antibiotic combinations for use against gram-positive bacteria |
| KR102426421B1 (ko) * | 2021-01-06 | 2022-07-29 | 주식회사 리신바이오 | 신규 재조합 엔도라이신 및 이의 용도 |
| WO2024007055A1 (en) * | 2022-07-05 | 2024-01-11 | The University Of Adelaide | Method of production of modified phage and method of treatment using same |
| WO2024149265A1 (zh) * | 2023-01-09 | 2024-07-18 | 华中农业大学 | 细菌裂解酶及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0285649A4 (en) | 1986-10-08 | 1990-06-27 | David Bernstein | METHOD FOR EXPOSING ANTIGENS OF GROUP A STREPTOCOCCUS AND IMPROVED DIAGNOSTIC TEST FOR THE IDENTIFICATION OF GROUP A STREPTOCOCCUS |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| EP1162994A4 (en) | 1999-02-25 | 2004-12-29 | New Horizons Diagnostics Inc | COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF STREPTOCOCCAL INFECTIONS |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US20040213765A1 (en) | 2001-07-13 | 2004-10-28 | Vincent Fischetti | Use of bacterial phage associated lytic enzymes to prevent food poisoning |
| EP1501925A4 (en) | 2002-05-17 | 2006-10-25 | New Horizons Diagnostics Corp | IDENTIFICATION OF A PHAGEN-ASSOCIATED LYTICAL ENZYME FOR THE FAST AND SPECIFIC DETECTION AND BUTTERFLY OF BACILLUS ANTHRACIS |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| EP1744779A2 (en) | 2004-03-24 | 2007-01-24 | The Rockfeller University | Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores |
| EP1621205A1 (en) * | 2004-07-28 | 2006-02-01 | OctoPlus Technologies B.V. | Antimicrobial peptides derived from CAP18 |
| EP2305294B1 (en) * | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
| US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| US8105585B2 (en) | 2005-08-24 | 2012-01-31 | The Rockefeller Universtiy | Ply-GBS mutant lysins |
| US20080019956A1 (en) | 2006-07-24 | 2008-01-24 | Manoj Kumar | Enzymatic prevention and control of biofilm |
| US8058225B2 (en) * | 2007-08-22 | 2011-11-15 | Hyglos Invest Gmbh | Proteins for use in human and animal Staphylococcus infections |
| US9056899B2 (en) * | 2008-01-10 | 2015-06-16 | Trustees Of Boston University | Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof |
| AU2009266982B2 (en) * | 2008-07-03 | 2015-06-25 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| CA2739717A1 (en) * | 2008-10-10 | 2010-04-15 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
| KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| WO2010125933A1 (ja) | 2009-05-01 | 2010-11-04 | 株式会社 きもと | 離型性組成物および表面保護フィルム |
| EP2338916A1 (en) * | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Chimeric polypeptides and their use in bacterial decoloniation |
| WO2011091412A1 (en) | 2010-01-25 | 2011-07-28 | Alere Scarborough, Inc. | A25 bacteriophage lysin |
| US9534223B2 (en) * | 2010-04-27 | 2017-01-03 | Lysando Ag | Method of reducing biofilms |
| EP2397548A1 (en) * | 2010-06-18 | 2011-12-21 | Hyglos Invest GmbH | Methods of generating and screening for lytic chimeric polypeptides |
| JP6139509B2 (ja) | 2011-04-21 | 2017-05-31 | ザ ロックフェラー ユニバーシティ | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2014519485A (ja) * | 2011-04-21 | 2014-08-14 | ユニベルシタイト ユトレヒト ホールディング ベーフェー | コンパニオン動物および家畜におけるグラム陽性細菌を処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| US20140120074A1 (en) | 2011-04-27 | 2014-05-01 | Lysando Ag | Antimicrobial agents |
| IL235527B2 (en) | 2012-05-09 | 2023-10-01 | Contrafect Corp | Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria |
| EP2835193A1 (en) | 2013-08-05 | 2015-02-11 | Refractory Intellectual Property GmbH & Co. KG | Refractory ceramic nozzle |
| CN104073478A (zh) * | 2014-06-13 | 2014-10-01 | 上海交通大学 | 杀灭革兰氏阳性菌的酶抗生素及其制备、用途 |
| CN104726439B (zh) * | 2015-04-13 | 2017-11-14 | 武汉菲吉乐科生物科技有限公司 | 一种广谱的链球菌裂解酶及其应用 |
| CN104805066B (zh) * | 2015-05-18 | 2018-04-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
| MX2018003101A (es) * | 2015-09-17 | 2018-12-17 | Contrafect Corp | Activo de polipeptidos de lisina contra bacterias gram-negativas. |
-
2013
- 2013-05-09 CA CA3187222A patent/CA3187222A1/en active Pending
- 2013-05-09 KR KR1020217030507A patent/KR20210118980A/ko not_active IP Right Cessation
- 2013-05-09 KR KR1020147034615A patent/KR102084388B1/ko active Application Filing
- 2013-05-09 ES ES13787555T patent/ES2729123T3/es active Active
- 2013-05-09 AU AU2013259427A patent/AU2013259427B2/en active Active
- 2013-05-09 CN CN201380036474.5A patent/CN104780933B/zh active Active
- 2013-05-09 RU RU2018102796A patent/RU2735103C2/ru active
- 2013-05-09 WO PCT/US2013/040340 patent/WO2013170022A1/en active Application Filing
- 2013-05-09 MX MX2014013587A patent/MX369056B/es active IP Right Grant
- 2013-05-09 DK DK13787555.5T patent/DK2846827T3/da active
- 2013-05-09 EP EP13787555.5A patent/EP2846827B1/en active Active
- 2013-05-09 US US14/399,588 patent/US9499594B2/en active Active
- 2013-05-09 JP JP2015511701A patent/JP6348901B2/ja active Active
- 2013-05-09 KR KR1020237030790A patent/KR20230135161A/ko active Application Filing
- 2013-05-09 BR BR112014027818-0A patent/BR112014027818B1/pt active IP Right Grant
- 2013-05-09 CA CA2872911A patent/CA2872911C/en active Active
- 2013-05-09 KR KR1020207005447A patent/KR20200023521A/ko active Application Filing
- 2013-05-09 IN IN2438MUN2014 patent/IN2014MN02438A/en unknown
- 2013-05-09 RU RU2014149348A patent/RU2646102C2/ru active
- 2013-05-09 EP EP19156777.5A patent/EP3513807A1/en active Pending
- 2013-05-09 CN CN202010800525.9A patent/CN111803620A/zh active Pending
-
2014
- 2014-11-06 IL IL235526A patent/IL235526B2/en unknown
- 2014-11-07 MX MX2019012877A patent/MX2019012877A/es unknown
-
2015
- 2015-09-17 HK HK15109108.3A patent/HK1208366A1/xx unknown
-
2016
- 2016-01-05 HK HK16100031.3A patent/HK1212208A1/xx unknown
- 2016-10-14 US US15/293,586 patent/US20170127683A1/en not_active Abandoned
-
2018
- 2018-02-23 JP JP2018031017A patent/JP6873939B2/ja active Active
- 2018-03-09 AU AU2018201736A patent/AU2018201736B2/en active Active
-
2019
- 2019-04-22 US US16/391,272 patent/US11524046B2/en active Active
- 2019-09-18 IL IL26942619A patent/IL269426A/en unknown
-
2020
- 2020-06-16 AU AU2020204014A patent/AU2020204014A1/en not_active Abandoned
- 2020-08-07 JP JP2020134278A patent/JP2020189860A/ja active Pending
- 2020-10-12 RU RU2020133461A patent/RU2020133461A/ru unknown
-
2022
- 2022-08-18 JP JP2022130371A patent/JP7368018B2/ja active Active
- 2022-11-11 US US18/054,587 patent/US20230277617A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2664708C1 (ru) * | 2017-06-08 | 2018-08-21 | Сергей Иванович Черныш | Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014149348A (ru) | Предотвращение, разрушение и обработка биопленки лизином бактериофага | |
| Angelopoulou et al. | Non-antibiotic microbial solutions for bovine mastitis–live biotherapeutics, bacteriophage, and phage lysins | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| RU2018107249A (ru) | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики | |
| ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
| Weiss et al. | Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo | |
| Lungren et al. | Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material | |
| WO2009111064A3 (en) | Minocycline compounds and methods of use thereof | |
| EP4332217A3 (en) | Antibacterial phage, phage peptides and methods of use thereof | |
| PH12020550107A1 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| NZ728429A (en) | Acinetobacter lysins | |
| HRP20161439T1 (hr) | Uporaba helatirajućeg sredstva i peptidnih atimikrobnih spojeva | |
| JP2013539776A5 (ru) | ||
| RU2019136978A (ru) | Антибактериальная композиция и способ лечения стафилококковых инфекций антибактериальной композицией | |
| Oksuz et al. | Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics | |
| WO2013041663A3 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| MX344183B (es) | Proteina antimicrobiana. | |
| EA202290048A1 (ru) | Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой | |
| RU2019138064A (ru) | Лиофилизированные композиции антибактериального белка | |
| MX2015015176A (es) | Composiciones antimicrobianas y metodos para su produccion. | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| MX2021012375A (es) | Metodo para tratar y prevenir infecciones oseas y de articulaciones. | |
| JP2017533177A5 (ru) | ||
| WO2010131865A3 (ko) | 항생제 내성 균주에 대한 항균용 조성물 |